Wer wir sind
Seit 1876 verbindet Eli Lilly and Company („Lilly“) Fürsorge mit Forschung, um Arzneimittel zu entwickeln, die das Leben von Menschen mit schweren Erkrankungen verändern. Von Beginn an lag der Fokus darauf, wissenschaftlich geprüfte, hochwertige Medikamente bereitzustellen und Standards für moderne pharmazeutische Herstellung und Forschung zu setzen.
Today, Lilly is a global biopharmaceutical company with a portfolio that includes therapies for diabetes, obesity, cardiovascular disease, neuroscience, immunology, and cancer. The company partners with healthcare professionals, patient organizations, and regulators worldwide to advance standards of care and expand access to innovative medicines.
Unser Zweck
Lillys erklärter Zweck ist es, „Arzneimittel zu entwickeln, die das Leben von Menschen weltweit verbessern“. Dieser Zweck prägt Entscheidungen in Forschung, Entwicklung, Herstellung und verantwortungsvoller Bereitstellung von Arzneimitteln wie Orforglipron.
For people living with chronic conditions like type 2 diabetes and obesity, this means a sustained commitment to advancing GLP‑1–based therapies, improving outcomes, and making treatments more convenient—such as exploring once‑daily oral options in addition to injectable medicines.
Tradition der Innovation
Over nearly 150 years, Lilly has been associated with a number of firsts in modern medicine, including early large‑scale production of insulin, development of important antibiotics and treatments for mental health conditions, and the introduction of new classes of medicines for diabetes and obesity.
Orforglipron is part of this ongoing heritage—an investigational, once‑daily oral GLP‑1 receptor agonist being studied for weight management and type 2 diabetes. It builds on decades of Lilly experience in metabolic disease research and on extensive global clinical trial programs.
Focus on diabetes, obesity and cardiometabolic health
- Multiple clinical programs in type 2 diabetes and obesity, including the ACHIEVE and ATTAIN trials
- Research into how GLP‑1–based medicines can improve glycemic control and support sustained weight loss
- Ongoing studies evaluating long‑term cardiovascular and renal outcomes
Putting patients and safety first
Every investigational medicine, including orforglipron, is evaluated in carefully controlled clinical trials designed to understand safety, tolerability, and benefit–risk balance. Lilly works closely with regulators such as the U.S. Food and Drug Administration (FDA) and other global health authorities to review data before a medicine is approved for routine use.